Treatment trends for clinically XXXX . National population analysis: GESCAP group.

@entity1 @entity263 @entity5 @entity11179
OBJECTIVES: To describe the established therapies for @entity263 ( @entity263 ) in Spain and to assess compliance with the 2010 UAE guidelines. @entity1 AND METHODS: This was an epidemiological, observational, prospective and multicentre study. Of the 3,918 @entity1 diagnosed with @entity263 during 2010, only those @entity1 with localised @entity263 were included. Follow-up was ultimately conducted for a minimum of one year from the diagnosis for 3,713 @entity1 (94.77%). The treatment groups assessed were as follows: radical prostatectomy, radiation therapy, hormone therapy, brachytherapy, active surveillance or observation and experimental local treatment (cryotherapy or other treatment). Compliance with the recommendations of the EAU guidelines was studied, describing the treatment groups according to D'Amico risk stratification criteria (localised [low, intermediate and high risk] and locally advanced), age, @entity11179 and Gleason score. RESULTS: By applying the D'Amico criteria, we included 3,641 (92.93%) @entity1 . Based on the UAE recommendations: 1) 68.87% of the @entity1 at low-intermediate risk aged <=65 years underwent radical prostatectomy; 2) 34.51% of the @entity1 >65 years at high risk with locally advanced disease were administered radiation therapy and hormone therapy; 3) 30.36% of the @entity1 at high risk with locally advanced disease were only treated with hormone therapy; 4) 15.20% of the @entity1 at low risk were only treated with brachytherapy; 5) active surveillance or observation was selected for 2.44% of the @entity1 aged <=65 years and for 10.63% of the @entity1 at low-intermediate risk who were>65 years. Lastly, 86.5% of the @entity1 at low risk underwent a single treatment, and 43.62% of the @entity1 at high risk with locally advanced disease underwent combined treatments. CONCLUSIONS: This is the first national European study to evaluate the therapeutic management of localised @entity263 based on the risk group to which the @entity1 belonged. Most young @entity1 ( <=65 years) with low-intermediate risk localised @entity263 were treated with surgery, which adheres to the recommendations of the 2010 UAE guidelines. Various therapeutic combinations have been employed for @entity1 with high-risk, locally advanced @entity5 , revealing the need for a multidisciplinary approach (Controlled-trials.com number: ISRCTN19893319).
